Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2021-08-10 00:00:00 ET · period of report 2021-08-06 · accession 0001708138-21-000048 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-08-10 | 2021-08-06 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Dir | M - OptEx | $52.03 | +400.0K | 596.2K | +204% | +$20.81M |
| DM | 2021-08-10 | 2021-08-06 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Dir | F - Tax | $607.51 | -228.6K | 504.7K | -31% | -$138.86M |
| DMI | 2021-08-10 | 2021-05-19 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Dir | G - Gift | $0.00 | 0 | 41.2K | New | $0 |
| DM | 2021-08-10 | 2021-08-06 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Dir | M - OptEx | $0.00 | -400.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-06 | M | A | 240,000 | $52.03 | 573,321 | D By Trust | — | — | (F2) These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. |
| 2 | Common | Common Stock | 2021-08-06 | F | D | 137,145 | $607.51 | 436,176 | D by 2019 GRAT | — | — | |
| 3 | Common | Common Stock | 2021-05-19 | G | D | 41,178 | $0.00 | 0 | I | — | — | |
| 4 | Common | Common Stock | 2021-08-06 | F | D | 91,430 | $607.51 | 504,746 | D | — | — | |
| 5 | Common | Common Stock | 2021-05-19 | G | A | 41,178 | $0.00 | 41,178 | I | — | — | |
| 6 | Common | Common Stock | 2021-08-06 | M | A | 160,000 | $52.03 | 596,176 | D | — | — | |
| 7 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-08-06 | M | D | 240,000 | $0.00 | 160,000 | D | $52.03 · — to 2021-12-16 | 240,000 Common Stock | (F3) With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 160,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. |
| 8 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-08-06 | M | D | 160,000 | $0.00 | 0 | D | $52.03 · — to 2021-12-16 | 160,000 Common Stock | (F3) With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 160,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. |